Difference between revisions of "Alisertib (MLN-8237)"
Jump to navigation
Jump to search
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
m |
||
| Line 1: | Line 1: | ||
=Mechanism of action= | =Mechanism of action= | ||
| − | Aurora A kinase | + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=561286 NCI Drug Dictionary]: A second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Alisertib binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation. |
=Preliminary results= | =Preliminary results= | ||
==[[Mantle cell lymphoma]]== | ==[[Mantle cell lymphoma]]== | ||
| − | |||
# Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014 Jan 1;32(1):44-50. Epub 2013 Sep 16. [http://jco.ascopubs.org/content/32/1/44.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24043741 PubMed] | # Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014 Jan 1;32(1):44-50. Epub 2013 Sep 16. [http://jco.ascopubs.org/content/32/1/44.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24043741 PubMed] | ||
| Line 12: | Line 11: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | [[Category: | + | [[Category:Oral medications]] |
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
[[Category:Aurora kinase inhibitors]] | [[Category:Aurora kinase inhibitors]] | ||
Revision as of 17:32, 29 October 2017
Mechanism of action
From the NCI Drug Dictionary: A second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Alisertib binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation.
Preliminary results
Mantle cell lymphoma
- Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014 Jan 1;32(1):44-50. Epub 2013 Sep 16. link to original article PubMed
Peripheral T-cell lymphoma
- Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, Friedberg JW. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. J Clin Oncol. 2015 Jul 20;33(21):2399-404. Epub 2015 Jun 15. link to original article PubMed